Search
Cisatracurium
go.drugbank.com/drugs/DB00565ApprovedInvestigational[A243416,A253592] Cisatracurium is an R-cis-R-cis isomer of [atracurium] and has approximately 3 times its neuromuscular blocking potency. … [A243416,A253592] Cisatracurium has an intermediate duration of action and is one of the most commonly used neuromuscular blocking agents in intensive care.[A253592,A253597].
Attapulgite
go.drugbank.com/drugs/DB01574ApprovedVet approvedWithdrawnAttapulgite is a magnesium aluminium phyllosilicate which occurs in a type of clay soil common to the Southeastern United States. When used in medicine, it physically binds to acids and toxic substances in the stomach and digestive tract...
Mixtures: Donnagel-PG CapRevefenacin
go.drugbank.com/drugs/DB11855ApprovedInvestigationalRevefenacin is a novel biphenyl carbamate tertiary amine agent that belongs to the family of the long-acting muscarinic antagonists (LAMA). The labile primary amide in the structure produces a "soft-drug" site that allows rapid systemic ...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesDoxercalciferol
go.drugbank.com/drugs/DB06410ApprovedInvestigationalD2. … Doxercalciferol is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1α,25-dihydroxyvitamin D2 (1α,25-(OH)2D2), a naturally occurring, biologically active form of vitamin
Categories: Vitamin D and AnaloguesSynonyms: 1-Hydroxyvitamin D2, 1α-hydroxyvitamin D2Eucalyptol
go.drugbank.com/drugs/DB03852ApprovedInvestigationalNutraceuticalEucalyptol is an ingredient in many brands of mouthwash and cough suppressant. It controls airway mucus hypersecretion and asthma via anti-inflammatory cytokine inhibition. … Eucalyptol is an effective treatment for nonpurulent rhinosinusitis. Eucalyptol reduces inflammation and pain when applied topically. It kills leukaemia cells in vitro.
Synonyms: 1,8-epoxy-p-menthane, 1,8-oxido-p-menthaneMixtures: Buenos Dias de Personna mint, Buenos Dias de Personna originalZafirlukast
go.drugbank.com/drugs/DB00549ApprovedZafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsFebuxostat
go.drugbank.com/drugs/DB04854ApprovedInvestigationalFebuxostat works by inhibiting the activity of an enzyme that is responsible for the synthesis of uric acid, thereby reducing serum uric acid levels. … [A230548] In the following year, the FDA for approved febuxostat for use in the chronic management of hyperuricemia in adult patients with gout who have an inadequate response or intolerance to [allopurinol
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesL-Glutamine
go.drugbank.com/drugs/DB00130ApprovedInvestigationalNutraceuticalIt is the principal carrier of nitrogen in the body and is an important energy source for many cells. … An oral formulation of L-glutamine was approved by the FDA in July 2017 for use in sickle cell disease [L892]. This oral formulation is marketed under the tradename Endari by Emmaus Medical.
Lorpiprazole
go.drugbank.com/drugs/DB09195ApprovedLorpiprazole is a serotonin antagonist and reuptake inhibitor used for the treatment of major depressive disorder. It is a piperazinyl-triazole derivative.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesModafinil
go.drugbank.com/drugs/DB00745ApprovedInvestigationalThe exact mechanism of action is unclear, although in vitro studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Substrates